Can Levodopa-Carbidopa Be Given Sublingually?
Yes, levodopa-carbidopa orally disintegrating tablets (ODT) can be given to patients who cannot swallow, as they are specifically designed to dissolve on the tongue without requiring water or swallowing. 1
FDA-Approved Orally Disintegrating Formulation
The FDA-approved carbidopa-levodopa orally disintegrating tablet is explicitly designed for patients with swallowing difficulties. The tablet should be placed on top of the tongue where it dissolves in seconds, then is swallowed with saliva—administration with liquid is not necessary. 1 This formulation is an immediate-release preparation that begins releasing ingredients within 30 minutes 1.
Administration Instructions:
- Remove tablet from bottle with dry hands just prior to dosing
- Immediately place on top of the tongue
- Allow to dissolve (occurs in seconds)
- Swallow with saliva
- No water required 1
Available Strengths
The orally disintegrating formulation comes in three ratios of carbidopa to levodopa:
- 25 mg/100 mg (1:4 ratio)
- 10 mg/100 mg (1:10 ratio)
- 25 mg/250 mg (1:10 ratio) 1
Clinical Context and Alternatives
While the ODT formulation addresses swallowing difficulties, it's important to understand this is not true sublingual absorption—the medication still requires some degree of swallowing with saliva. For patients who are truly nil-by-mouth or have severe dysphagia where even saliva cannot be swallowed safely, alternative routes are necessary 2, 3.
When ODT Is Insufficient:
For patients who cannot manage even the ODT formulation, consider:
- Nasogastric tube with dispersible levodopa preparations 2, 3
- Transdermal rotigotine patches (dopamine agonist, not levodopa) 3
- Subcutaneous apomorphine (dopamine agonist) 3
- Levodopa-carbidopa intestinal gel (LCIG) for advanced disease 4
Critical Pitfall
Do not confuse "orally disintegrating" with true sublingual absorption. While one case report describes using crushed standard levodopa tablets sublingually in the perioperative setting 5, this is off-label and lacks robust evidence. The ODT formulation is designed to dissolve and be swallowed with saliva, not absorbed through the oral mucosa. If the patient cannot swallow saliva, the ODT will not work effectively.
Timing Considerations
Never delay or omit dopaminergic medications in Parkinson's disease patients, as this can precipitate neuroleptic malignant-like syndrome—a life-threatening complication 3. The ODT formulation provides rapid dissolution but maintains the same immediate-release pharmacokinetics as standard tablets, so timing intervals should remain consistent with the patient's usual regimen 1.